PharmaVentures announces launch of ddcr.com New web site to enable drug delivery deal making

Oxford, UK 17^th March 2005 – PharmaVentures announces the launch of its new web site, ddcr.com, giving access to current drug delivery deal making opportunities and key facts and trends affecting the drug delivery market. 

Dr Fintan Walton, PharmaVentures’ CEO said, “We wanted to provide a valuable resource for people involved in drug delivery to facilitate their partnering activities and drive ongoing product development.” 

ddcr.com contains live deal making opportunities, current industry news, profiles of drug delivery companies, including a product and service locator, and details of the corporate relationships these companies are seeking. Articles from the report are contained within ddcr.com along with a useful section of industry links and an events calendar listing conferences relevant to the drug delivery industry. 

Dr Walton goes on to say “Both ddcr.com and Drug Delivery E-News underpin our already successful Drug Delivery Companies Report. Drug delivery companies can submit their opportunities and get them in front of the people who are really doing deals.” 

The Drug Delivery Companies Report has been established for over 10 years. Published bi-annually, it is relied upon within the industry as the main method of independently assessing drug delivery partners, trends and developments to enable drug delivery deal making. 

-Ends- 

For further information please contact: 

Mel Hemamda
Drug Delivery Product Manager
PharmaVentures

Tel: +44 (0) 1865 784 180
Fax: +44 (0) 1865 784 178

E-mail: enquiries@pharmaventures.com

Web: www.pharmaventures.com

Editor’s Notes:

PharmaVentures is a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas – PharmaVentures Consulting and PharmaVentures Intelligence, we work with our clients to drive greater value from their deals. Based in Oxford, UK the company employs over 30 people and has offices in the USA.